Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma

NCT06653517 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Ameloblastoma
BRAF V600E Mutation Positive

Interventions

DRUG: Dabrafenib
DRUG: Trametinib

Sponsor

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University